Program
Oxymetazoline
Also written as “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, “Oxymetazoline Hydrochloride” and “Oxymetazoline HCL Cream 1.0%”.
Its studies are mostly in Rosacea · Erythema · Fecal Incontinence · Rhinitis, Allergic · Nasal Obstruction, led by 10 companies.
Drug pageOxymetazoline: every studyMany companies study it; this page follows only the 16 they lead. All 44 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 60 open or running | phase 3since Mar 21, 2014 | Apr 13, 2012 | none ahead |
| RDD Pharmaits history only | 20 open or running | phase 2since Nov 17, 2014 | Nov 17, 2014 | none ahead |
| Aclaris Therapeuticsits history only | 10 open or running | phase 4since Dec 18, 2017 | Dec 18, 2017 | none ahead |
| Bayerits history only | 10 open or running | phase 2since May 6, 2026 | May 6, 2026 | none ahead |
| Eye Therapies | 10 open or running | phase 2since Jan 10, 2011 | Jan 10, 2011 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since May 30, 2014 | May 30, 2014 | none ahead |
| Padagisits history only | 10 open or running | phase 3since Nov 7, 2017 | Nov 7, 2017 | none ahead |
| Santen Pharmaceuticalits history only | 11 open or running | phase 3since Jul 3, 2024 | Jul 3, 2024 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Nov 23, 2021 | Nov 23, 2021 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Apr 10, 2019 | Apr 10, 2019 | none ahead |
Also a collaborator on its studies: Quintiles, Ground Zero Pharmaceuticals, Rho and ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eye Therapies only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 10, 2011First study: phase 2 study in Conjunctivitis, AllergicFirst studyNCT01275105 · 68 enrolled · United States
TargetBeta
“Adrenergic receptor alpha agonist”ChEMBL 37, by rule
Other programs on the same 6 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
The one study Eye Therapies leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01275105Conjunctivitis, Allergic · United States | 2 | Completed | Mar 2011 | 68 |
How it is read
Names in the registry
- “Oxymetazoline”, 3 entries
- “OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)”, 2 entries
- “Oxymetazoline Hydrochloride”, 2 entries
- “Oxymetazoline HCL Cream 1.0%”, 2 entries
- “AGN-199201”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 5 studies
- Erythema, 3 studies
- Fecal Incontinence, 2 studies
- Rhinitis, Allergic, 2 studies
- Nasal Obstruction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.